What's in a name? The future of drug-resistant tuberculosis classification

The Lancet Infectious Diseases

Volumn 13, Issue 4, 2013, Pages 373-376

  Sullivan, Timothy ^a   Amor, Yanis Ben ^b  

^a MOUNT SINAI HOSPITAL   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMIKACIN; AMINOSALICYLIC ACID; BEDAQUILINE; CAPREOMYCIN; DELAMANID; ETHAMBUTOL; ISONIAZID; KANAMYCIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SERINE DERIVATIVE; THIOAMIDE; TUBERCULOSTATIC AGENT;

DISEASE CLASSIFICATION; DRUG RESISTANT TUBERCULOSIS; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HEALTH CARE COST; HUMAN; LABORATORY; MEDICAL TERMINOLOGY; MULTIDRUG RESISTANT TUBERCULOSIS; NOTE; PRIORITY JOURNAL; TUBERCULOSIS; TUBERCULOSIS CONTROL; WORLD HEALTH ORGANIZATION;

ANTITUBERCULAR AGENTS; DRUG THERAPY, COMBINATION; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TERMINOLOGY AS TOPIC; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84875585584     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(12)70318-3     Document Type: Note

References (27)

1. Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C Totally drug-resistant tuberculosis in India. Clin Infect Dis 2012, 54:579-581.
2. Migliori GB, De Iaco G, Besozzi G, Centis R, Cirillo DM First tuberculosis cases in Italy resistant to all tested drugs. Euro Surveill 2007, 12. E070517 1.
3. Velayati AA, Masjedi MR, Farnia P, et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest 2009, 136:420-425.
4. "Totally Drug-Resistant TB": a WHO consultation on the diagnostic definition and treatment options 2012, WHO, World Health Organization, Geneva, Switzerland.
5. Waksman SA Streptomycin: background, isolation, properties, and utilization. Nobel Lectures: Physiology or Medicine, 1942-1962 1964, 370-388. Elsevier, Amsterdam.
6. Hinman AR, Hughes JM, Snider DE, Cohen ML Meeting the challenge of multidrug-resistant tuberculosis: summary of a conference. MMWR Recomm Rep 1992, 41:51-57.
7. Report of the meeting of the WHO Global Task Force on XDR-TB 2006, WHO, World Health Organization, Geneva, Switzerland.
8. Ben Amor Y, Day MS, Schluger NW Preventing the next generation of extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis 2010, 14:525-527.
9. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 2006, 55:301-305. Centers for Disease Control and Prevention (CDC).
10. Shah NS, Wright A, Drobniewski F, Rusch-Gerdes S, Havelkova M, Gilpin C Extreme drug resistance in tuberculosis (" XDR-TB"): global survey of supranational reference laboratories for Mycobacterium tuberculosis with resistance to second line drugs. Int J Tuberc Lung Dis 2005, 9(suppl):S77.
11. Kim SJ Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur Respir J 2005, 25:564-569.
12. Kim SJ, Espinal MA, Abe C, et al. Is second-line anti-tuberculosis drug susceptibility testing reliable?. Int J Tuberc Lung Dis 2004, 8:1157-1158.
13. Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. Wkly Epidemiol Rec 2006, 81:430-432. WHO.
14. Cegielski P, Nunn P, Kurbatova EV, et al. Challenges and controversies in defining totally drug-resistant tuberculosis. Emerg Infect Dis 2012, 18:e2.
15. Farley JE, Ram M, Pan W, et al. Outcomes of multi-drug resistant tuberculosis (MDR-TB) among a cohort of South African patients with high HIV prevalence. PLoS One 2011, 6:e20436.
16. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response 2010, WHO, World Health Organization, Geneva, Switzerland.
17. Kim HR, Hwang SS, Kim HJ, et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis 2007, 45:1290-1295.
18. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006, 368:1575-1580.
19. The global plan to stop TB 2011-2015: transforming the fight towards elimination of tuberculosis 2010, WHO, World Health Organization, Geneva, Switzerland.
20. Ma Z, Lienhardt C, McIlleron H, Nunn AJ, Wang X Global tuberculosis drug development pipeline: the need and the reality. Lancet 2010, 375:2100-2109.
21. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009, 360:2397-2405.
22. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012, 366:2151-2160.
23. Schecter GF, Scott C, True L, Raftery A, Flood J, Mase S Linezolid in the treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2010, 50:49-55.
24. Willyard C Race heats up for first-to-market drugs for resistant tuberculosis. Nat Med 2012, 18:1157.
25. Evaluation of 8 weeks of treatment with the combination of moxifloxacin, PA-824 and pyrazinamide in patients with drug sensitive and multi drug-resistant pulmonary tuberculosis (TB) ClinicalTrials.gov, (accessed Dec 14, 2012). http://clinicaltrials.gov/ct2/show/NCT01498419.
26. Evaluation of early bactericidal activity in pulmonary tuberculosis with(J-M-Pa-Z) ClinicalTrials.gov, (accessed Dec 14, 2012). http://clinicaltrials.gov/ct2/show/NCT01215851.
27. Global tuberculosis report 2012 2012, WHO, World Health Organization, Geneva, Switzerland.